Apollo Therapeutics, a Cambridge UK-based biopharmaceutical company focused on advancing treatments based on breakthrough discoveries, raised $145M in funding.
The round was led by Patient Square Capital, with participation from Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. In conjunction with the financing, Jim Momtazee, Managing Partner of Patient Square Capital, will join Apollo’s Board of Directors.
The company intends to use the funds to advance its pipeline into development across oncology, major inflammatory disorders and rare disease, expand its U.S. operations in Boston area, and pursue collaborations globally with leading academic institutions.
Led by Dr. Richard Mason, CEO, Dr. Richard Butt, chief scientific officer, Jamie Heath, chief financial officer, and Arjun Krishnan, chief business officer, Apollo Therapeutics is a portfolio-based biopharmaceutical company advancing potentially transformative treatments based on breakthrough discoveries. The company was originally established in late 2015 as a joint venture between the University of Cambridge, Imperial College London (then subsequently IP Group Plc), University College London, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson Innovation to set-up to to develop therapeutics that have transformative potential above the current standard of care. The company evaluates breakthrough scientific discoveries across multiple criteria, including having a compelling and testable biological hypothesis or having a differentiated mechanism or technology compared to other therapeutics in development or on the market.